kemalbas
Shares of Repare Therapeutics (NASDAQ:RPTX) plunged 38% in post-market trading Thursday after the company reported Phase 1 data on its drugs lunresertib and camonsertib as a combination therapy for endometrial and ovarian cancer.
The data showed the combination achieved a